(Q36396043)

13 August 2017

0 references

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL (English)

1 reference

13 August 2017

0 references

1 reference

1 reference

3

Shyam Kottilil

1 reference

13 August 2017

4

Ruth M Pfeiffer

1 reference

13 August 2017

Thomas R O'Brien

1

1 reference

PMCID

4688210

13 August 2017

Jordan J Feld

series ordinal

2

1 reference

PMCID

4688210

13 August 2017

language of work or name

English

0 references

publication date

16 October 2015

1 reference

13 August 2017

1 reference

13 August 2017

63

1 reference

13 August 2017

28-30

1 reference

13 August 2017

1

1 reference

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688210

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688210

Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688210

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688210

Therapy for hepatitis C--the costs of success

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4688210

EASL Recommendations on Treatment of Hepatitis C 2015

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FHEP.28292

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26474163

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/HEP.28292

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

PMCID

4688210